Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
6320 | 1434 | 51.0 | 89% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
128 | 23028 | EPENDYMOMA//MEDULLOBLASTOMA//GLIOBLASTOMA |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | EGFRVIII | Author keyword | 61 | 53% | 6% | 80 |
2 | RECURRENT GLIOBLASTOMA | Author keyword | 22 | 49% | 2% | 33 |
3 | TUMOR TREATING FIELDS | Author keyword | 21 | 90% | 1% | 9 |
4 | P TON ROBERT TI BRAIN TUMOR | Address | 10 | 22% | 3% | 39 |
5 | ONCOGEN SIGNALLING | Address | 7 | 57% | 1% | 8 |
6 | STEPHEN E CATHERINE P PAS NEUROONCOL | Address | 7 | 31% | 1% | 18 |
7 | NOVOTTF 100A | Author keyword | 6 | 80% | 0% | 4 |
8 | NEUROONCOL BRANCH | Address | 6 | 19% | 2% | 29 |
9 | DELTA EGFR | Author keyword | 6 | 100% | 0% | 4 |
10 | TEMOZOLOMIDE REFRACTORY | Author keyword | 6 | 100% | 0% | 4 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | EGFRVIII | 61 | 53% | 6% | 80 | Search EGFRVIII | Search EGFRVIII |
2 | RECURRENT GLIOBLASTOMA | 22 | 49% | 2% | 33 | Search RECURRENT+GLIOBLASTOMA | Search RECURRENT+GLIOBLASTOMA |
3 | TUMOR TREATING FIELDS | 21 | 90% | 1% | 9 | Search TUMOR+TREATING+FIELDS | Search TUMOR+TREATING+FIELDS |
4 | NOVOTTF 100A | 6 | 80% | 0% | 4 | Search NOVOTTF+100A | Search NOVOTTF+100A |
5 | DELTA EGFR | 6 | 100% | 0% | 4 | Search DELTA+EGFR | Search DELTA+EGFR |
6 | TEMOZOLOMIDE REFRACTORY | 6 | 100% | 0% | 4 | Search TEMOZOLOMIDE+REFRACTORY | Search TEMOZOLOMIDE+REFRACTORY |
7 | RECURRENT MALIGNANT GLIOMA | 5 | 41% | 1% | 9 | Search RECURRENT+MALIGNANT+GLIOMA | Search RECURRENT+MALIGNANT+GLIOMA |
8 | HIGH GRADE GLIOMA | 4 | 11% | 3% | 36 | Search HIGH+GRADE+GLIOMA | Search HIGH+GRADE+GLIOMA |
9 | RECURRENT GLIOBLASTOMA MULTIFORME | 3 | 40% | 0% | 6 | Search RECURRENT+GLIOBLASTOMA+MULTIFORME | Search RECURRENT+GLIOBLASTOMA+MULTIFORME |
10 | RINDOPEPIMUT | 3 | 50% | 0% | 4 | Search RINDOPEPIMUT | Search RINDOPEPIMUT |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SINGLE AGENT BEVACIZUMAB | 123 | 81% | 5% | 75 |
2 | BRAIN TUMOR CONSORTIUM | 111 | 64% | 8% | 109 |
3 | BEVACIZUMAB PLUS IRINOTECAN | 71 | 44% | 8% | 120 |
4 | CONFERS ENHANCED TUMORIGENICITY | 62 | 56% | 5% | 75 |
5 | RECURRENT MALIGNANT GLIOMA | 48 | 32% | 9% | 127 |
6 | RECURRENT GLIOBLASTOMA | 40 | 27% | 9% | 126 |
7 | NEWLY DIAGNOSED GLIOBLASTOMA | 39 | 22% | 11% | 157 |
8 | NEURO ONCOLOGIA GICNO | 35 | 89% | 1% | 16 |
9 | HIGH GRADE GLIOMAS | 34 | 15% | 14% | 200 |
10 | RECURRENT GLIOBLASTOMA MULTIFORME | 20 | 25% | 5% | 69 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Standards of care for treatment of recurrent glioblastoma-are we there yet? | 2013 | 54 | 99 | 62% |
Bevacizumab and Glioblastoma: Scientific Review, Newly Reported Updates, and Ongoing Controversies | 2015 | 1 | 63 | 73% |
Malignant gliomas in adults | 2008 | 1103 | 102 | 18% |
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? | 2013 | 64 | 135 | 28% |
The EGFRvIII variant in glioblastoma multiforme | 2009 | 117 | 96 | 69% |
Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma | 2015 | 1 | 33 | 45% |
Epidermal growth factor receptor: a re-emerging target in glioblastoma | 2012 | 31 | 41 | 61% |
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered | 2013 | 20 | 226 | 54% |
Pathway inhibition: emerging molecular targets for treating glioblastoma | 2011 | 58 | 75 | 45% |
Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors | 2013 | 17 | 99 | 57% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | P TON ROBERT TI BRAIN TUMOR | 10 | 22% | 2.7% | 39 |
2 | ONCOGEN SIGNALLING | 7 | 57% | 0.6% | 8 |
3 | STEPHEN E CATHERINE P PAS NEUROONCOL | 7 | 31% | 1.3% | 18 |
4 | NEUROONCOL BRANCH | 6 | 19% | 2.0% | 29 |
5 | HENRY E SINGLETON BRAIN TUMOR PROGRAM | 5 | 54% | 0.5% | 7 |
6 | CANC NEUROL | 4 | 44% | 0.5% | 7 |
7 | EPITHELIAL BIOCHEM | 4 | 46% | 0.4% | 6 |
8 | TUMOR TARGETING PROGRAM | 3 | 50% | 0.3% | 5 |
9 | SECT 6321 | 3 | 33% | 0.6% | 8 |
10 | SAN DIEGO BRANCH | 3 | 22% | 0.8% | 12 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000232672 | TEMOZOLOMIDE//GLIOBLASTOMA MULTIFORME//ANAPLASTIC ASTROCYTOMA |
2 | 0.0000191848 | IDH1//IDH2//ISOCITRATE DEHYDROGENASE 1 |
3 | 0.0000180505 | BRAIN TUMOR STEM CELL//GLIOMA STEM CELLS//BRAIN TUMOR STEM CELLS |
4 | 0.0000128402 | MTIC//DIPARTIMENTO FARMACOCHIM TOSSICOL BIOL//VLAK PROTOCOL |
5 | 0.0000121872 | OLIGODENDROGLIOMA//OLIGOASTROCYTOMA//19Q |
6 | 0.0000117745 | PSEUDOPROGRESSION//GLIOMA GRADING//MACDONALD CRITERIA |
7 | 0.0000111149 | HUMAN MALIGNANT GLIOMAS//MOL EXPT RADIOL//RADGENOM GRP |
8 | 0.0000100434 | NIMOTUZUMAB//H R3//CETUXIMAB |
9 | 0.0000082993 | CONVECTION ENHANCED DELIVERY//GLIADEL//CARMUSTINE WAFERS |
10 | 0.0000082940 | EGF DEXTRAN//ANTIBODY BINDING PARAMETERS//BIOMED RADIAT SCI |